DigestRedComo funciona
Red
/
Empresas
Al
No verificado

Alnylam Pharmaceuticals, Inc.

Sobre qué escribimos

BiotecnologíaFarmacéuticaMedicina - VariosSaludWeb y redes sociales

56 Comunicados de prensa

Ver todos los comunicados de prensa
17/12/2025
Industria
Biotecnología
Higiene alimentaria
Salud
Farmacéutica
Alnylam to Invest $250 Million to Add Enzymatic Ligation Platform to U.S. Manufacturing Facility to Meet Growing Global Demand for RNAi Therapeutics
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
11/12/2025
Acciones y Obligaciones
Biotecnología
Farmacéutica
Salud
Alnylam Announces Partial Repurchase of 1.00% Convertible Senior Notes Due 2027
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
03/12/2025
Mercado laboral
Biotecnología
Farmacéutica
Salud
Alnylam Pharmaceuticals Announces Changes to Board of Directors
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
08/11/2025
Ciencia
Cardiología
Biotecnología
Farmacéutica
Salud
Higiene alimentaria
Medicina - Varios
Eventos
Análisis de Mercados
New Post Hoc Analysis from the HELIOS-B Phase 3 Study Shows Vutrisiran Improved Measures of Heart Structure and Function in Patients with ATTR-CM
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
04/11/2025
Web y redes sociales
Eventos
Finanzas
Biotecnología
Farmacéutica
Salud
Alnylam to Webcast Presentations at Upcoming November Investor Conferences
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
30/10/2025
Web y redes sociales
Telefonía
Mercado de valores
Biotecnología
Salud
Farmacéutica
Medicina - Varios
Cardiología
Alnylam Pharmaceuticals Reports Third Quarter 2025 Financial Results and Highlights Recent Period Progress
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
16/10/2025
Biotecnología
Farmacéutica
Salud
Web y redes sociales
Telefonía
Finanzas
Mercado de valores
Alnylam to Webcast Conference Call Discussing Third Quarter 2025 Financial Results
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
01/10/2025
Biotecnología
Farmacéutica
Salud
Cardiología
Industria
Alnylam Announces First Patient Dosed in ZENITH Global Phase 3 Cardiovascular Outcomes Trial of Zilebesiran
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
29/09/2025
Biotecnología
Farmacéutica
Salud
Cardiología
Eventos
Industria
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0
28/09/2025
Biotecnología
Farmacéutica
Salud
Cardiología
Eventos
Industria
New Data from HELIOS-B Phase 3 Study Demonstrate Lower Rates of Gastrointestinal Events in ATTR-CM Patients Treated with Vutrisiran
Fuente
Alnylam Pharmaceuticals, Inc.
Editor
Business Wire
1.00
0

Detalles de contacto

Redes sociales

Seguidores
0
Compatibilidad
0